+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Alkermes plc - logo

Alkermes is a leader in innovative medicines that address the needs of people living with debilitating diseases. Alkermes develops products that are designed to make a meaningful difference in the way patients manage their disease. Alkermes produces innovative treatments for major clinical conditions specifically focused on central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis.

GABA Receptor Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

GABA Receptor Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Kappa Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Kappa Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
D1 Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

D1 Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Depression - Pipeline Review, H2 2020 - Product Thumbnail Image

Depression - Pipeline Review, H2 2020

  • Drug Pipelines
  • September 2020
  • 737 Pages
  • Global
From
Multiple Sclerosis - Market Insight, Epidemiology and Market Forecast -2032 - Product Thumbnail Image

Multiple Sclerosis - Market Insight, Epidemiology and Market Forecast -2032

  • Report
  • January 2022
  • 276 Pages
  • Global
From
Extractables and Leachables Testing Services Market, 2018-2028 - Product Thumbnail Image

Extractables and Leachables Testing Services Market, 2018-2028

  • Report
  • September 2018
  • 200 Pages
  • Global
From
Multiple Sclerosis: Dynamic Market Forecast to 2026 - Product Thumbnail Image

Multiple Sclerosis: Dynamic Market Forecast to 2026

  • Report
  • November 2018
  • 53 Pages
  • Global
From
Chondrosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Chondrosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • October 2022
  • 116 Pages
  • Global
From
Controlled Substance Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025 - Product Thumbnail Image

Controlled Substance Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025

  • Report
  • January 2020
  • 100 Pages
  • Global
From
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • August 2022
  • 137 Pages
  • Global
From
Head And Neck Cancer - Pipeline Review, H2 2020 - Product Thumbnail Image

Head And Neck Cancer - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 3419 Pages
  • Global
From
Gastric Cancer - Pipeline Review, H2 2020 - Product Thumbnail Image

Gastric Cancer - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 2657 Pages
  • Global
From
Huntington Disease - Pipeline Review, H1 2020 - Product Thumbnail Image

Huntington Disease - Pipeline Review, H1 2020

  • Drug Pipelines
  • June 2020
  • 390 Pages
  • Global
From
Alkermes, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis - Product Thumbnail Image

Alkermes, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

  • Company Profile
  • April 2025
  • 50 Pages
From
Comprehensive Report on Alkermes plc, including SWOT, PESTLE and Business Model Canvas - Product Thumbnail Image

Comprehensive Report on Alkermes plc, including SWOT, PESTLE and Business Model Canvas

  • SWOT Analysis
  • August 2023
  • 90 Pages
From
Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review - Product Thumbnail Image

Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review

  • SWOT Analysis
  • May 2024
  • 57 Pages
From
Loading Indicator